Brazil's API Market Anylysis

- Jun 01, 2018 -

 As one of the emerging markets, Brazil has a population of 200 million and is the largest country in South America, with GDP ranking sixth in the world.

 According to statistics, Brazil’s pharmaceutical market totaled 26 billion U.S. dollars. Due to President Lula’s social income distribution plan, the number of middle class has increased dramatically, more and more poor families have emerged from poverty and can afford affordable pharmaceutical products. It grows at a rate of about 10%.

 There are 270 private pharmaceutical companies and 20 state-owned pharmaceutical companies in Brazil. Multinational pharmaceutical giants such as Pfizer, Roche and Novartis have production bases in Brazil and supply products to markets in Brazil and other Latin American countries.

Brazil's Ministry of Development Industry has issued Complexo Industrial da Saúde (Health Complex Industry) as a priority development plan, and the National Development Bank (banco nacional do desenvolvimento BNDES) provides special financial support for industrial investment and exports, and also provides development for the pharmaceutical industry in the country. Great support.

Brazil's ANVISA has introduced some mandatory certification systems. In recent years, Brazil has made great progress in the pharmaceutical industry and its use of drugs. Being a Brazilian marketer, it is very obvious that the market is becoming more and more standard and the threshold for entry is getting more and more. high.

 The Brazilian government launched a generic drug program to promote cheap patented drugs. For these reasons, the companies in the country have also achieved good development, such as the private companies Cristalia, EMS, Ache, Eurofarma, Brasil Farma, and the state-owned companies Fiocruz and Butanta.

 A large proportion of finished products in Brazil are produced in the country, but pharmaceutical machinery and APIs are heavily dependent on imports. According to the survey, most of Brazil's pharmaceutical machinery is obsolete and needs to be replaced, so the market is about 50 to 100 million U.S. dollars, while Brazil can only produce packaging machinery, and other countries rely heavily on imports. Brazil imports raw material APIs each year up to 2 billion U.S. dollars, while few domestic raw material drug manufacturers rely almost entirely on imports.

 The development of new drugs in Brazil lags behind, unlike pharmaceutical giants such as Europe and the United States, which are the mainstream of new drug research and development. Brazil’s large-scale R&D is mainly carried out by state-owned universities and research institutes, accounting for more than 90% of all research, and some preclinical and toxicological studies are It is even impossible to carry out in Brazil. There are more than 100 privately owned biotechnology companies in Brazil that conduct some innovative research, but the scale is relatively small. Most of them are found in the university's entrepreneurial park and are created by university teachers and students.

About 1 billion U.S. dollars in the Brazilian plant drug market, relying on Brazil's diverse biotechnology, may have better development in the future. Brazil produces about 260 million human and veterinary vaccines each year, but most of them are produced by domestic companies and provided by the government to nationals.

  The Brazilian market is special. There are great differences with Europe and the United States. The differences with the Chinese market are even greater. Many Chinese companies have rushed into the country without investigating and losing. Entering the Brazilian market requires professional advice and assistance.

Related News

Related Products

  • Meldrum's Acid 2033-24-1
  • Tosyl Azide 941-55-9
  • Dodecylbenzenesulfonyl Azide 79791-38-1
  • P-Nitrobenzyl 2-diazoacetoacetate
  • 4-nitrobenzyl 2-diazo-3-oxobutanoate
  • Fomesafene